AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Elevance Health Plunges 6.17% on Lowered Earnings Outlook
Generated by AI AgentAinvest Movers Radar
Tuesday, May 13, 2025 7:53 am ET1min read
On May 13, 2025, Elevance Health's stock experienced a significant drop of 6.17% in pre-market trading, indicating a notable shift in investor sentiment.
Analysts have revised their expectations for Elevance Health's second-quarter earnings, with K. Dey from Zacks Research now projecting earnings per share of $9.36, down from the previous estimate of $9.85. This adjustment reflects a more cautious outlook on the company's financial performance.
Zacks' proprietary data rates
as a Zacks Rank 3, suggesting an inline return for investors. This rating is based on a comprehensive analysis of the company's financial health and market position, providing a balanced view of its potential for growth.Elevance Health has also provided guidance for its 2025 adjusted earnings per share from continuing operations, expecting a range of $4.85 to $5.10. This guidance offers investors a clearer picture of the company's anticipated financial performance for the year, helping to manage expectations and inform investment decisions.
Ainvest Movers Radar
Knowing stock market today at a glance
Latest Articles
Sabre (SABR) Soars 1.35% on Unexplained Rally to 5.41% Intraday High
Dec.23 2025
SRx Health (SRXH) 20.93% Plunge: Earnings Misses, Mixed Signals Spur Sharpest Selloff Since 2023
Dec.23 2025
XTKG Plunges 14.29% to Monthly Low on Earnings Woes, Operational Instability
Dec.23 2025
Arm Holdings Dives 20% as High Rates, Valuation Disconnect Dampen Demand
Dec.23 2025
Coupang Stock Plunge 3.71% to 2025 Low Amid Lawsuits Data Breach Fallout
Dec.23 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet